AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Chemomab Therapeutics Ltd. Statistics
Share Statistics
Chemomab Therapeutics Ltd. has 18.86M shares outstanding. The number of shares has increased by 38.42% in one year.
Shares Outstanding | 18.86M |
Shares Change (YoY) | n/a |
Shares Change (QoQ) | 31.32% |
Owned by Institutions (%) | n/a |
Shares Floating | 16.57M |
Failed to Deliver (FTD) Shares | 49.41K |
FTD / Avg. Volume | 42.45% |
Short Selling Information
The latest short interest is 162.90K, so 0.86% of the outstanding shares have been sold short.
Short Interest | 162.90K |
Short % of Shares Out | 0.86% |
Short % of Float | 0.98% |
Short Ratio (days to cover) | 1.15 |
Valuation Ratios
The PE ratio is -0.25 and the forward PE ratio is -46.25.
PE Ratio | -0.25 |
Forward PE | -46.25 |
PS Ratio | 0 |
Forward PS | 1.5 |
PB Ratio | 0.35 |
P/FCF Ratio | -0.25 |
PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Chemomab Therapeutics Ltd..
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.32, with a Debt / Equity ratio of 0.
Current Ratio | 4.32 |
Quick Ratio | 4.32 |
Debt / Equity | 0 |
Total Debt / Capitalization | 0 |
Cash Flow / Debt | 0 |
Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -1.43% and return on capital (ROIC) is -146.41%.
Return on Equity (ROE) | -1.43% |
Return on Assets (ROA) | -1.09% |
Return on Capital (ROIC) | -146.41% |
Revenue Per Employee | 0 |
Profits Per Employee | -1.21M |
Employee Count | 20 |
Asset Turnover | 0 |
Inventory Turnover | 0 |
Taxes
Income Tax | 0 |
Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 246.15% in the last 52 weeks. The beta is 0.3, so Chemomab Therapeutics Ltd.'s price volatility has been higher than the market average.
Beta | 0.3 |
52-Week Price Change | 246.15% |
50-Day Moving Average | 1.74 |
200-Day Moving Average | 1.32 |
Relative Strength Index (RSI) | 49.68 |
Average Volume (20 Days) | 116.40K |
Income Statement
Revenue | n/a |
Gross Profit | -66.83K |
Operating Income | -25.46M |
Net Income | -24.22M |
EBITDA | -25.39M |
EBIT | n/a |
Earnings Per Share (EPS) | -2.06 |
Balance Sheet
The company has 9.29M in cash and 392.00K in debt, giving a net cash position of 8.90M.
Cash & Cash Equivalents | 9.29M |
Total Debt | 392.00K |
Net Cash | 8.90M |
Retained Earnings | -88.68M |
Total Assets | 20.90M |
Working Capital | 15.54M |
Cash Flow
In the last 12 months, operating cash flow was -23.61M and capital expenditures -3.00K, giving a free cash flow of -23.61M.
Operating Cash Flow | -23.61M |
Capital Expenditures | -3.00K |
Free Cash Flow | -23.61M |
FCF Per Share | -2.01 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
CMMB does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | -108.99% |
FCF Yield | -66.26% |
Analyst Forecast
The average price target for CMMB is $7.5, which is 296.8% higher than the current price. The consensus rating is "Buy".
Price Target | $7.5 |
Price Target Difference | 296.8% |
Analyst Consensus | Buy |
Analyst Count | 2 |
Stock Splits
The last stock split was on Mar 17, 2021. It was a backward split with a ratio of 1:16.
Last Split Date | Mar 17, 2021 |
Split Type | backward |
Split Ratio | 1:16 |
Scores
Altman Z-Score | -2.19 |
Piotroski F-Score | 2 |